Prevalence and Incidence of Psoriatic Arthritis among Patients with Psoriasis and Risk Factors for Psoriatic Arthritis in Republic of Korea: A Nationwide Database Cohort Study
DOI:
https://doi.org/10.2340/actadv.v104.40110Keywords:
Epidemiology, Incidence, Prevalence, Psoriasis, Psoriatic arthritis, Risk factorAbstract
Population-based epidemiological studies on disease burden and risk factors for psoriatic arthritis (PsA) in patients with psoriasis (PsO) are limited, especially in Asian populations. Therefore, the aim was to determine the prevalence and incidence of PsA among PsO patients in Korea, and examine associated clinical factors. A cohort study was performed to determine the annual prevalence and incidence of PsA among PsO patients between 2008 and 2020 using nationwide claims data in Korea. Risk factors for PsA development were also examined using logistic regression among matched PsA cases and controls. An increasing trend in PsA prevalence per 1,000 patients was observed; prevalence was 6.17 (95% confidence interval [CI] 5.73–6.65) in 2008 and 19.03 (95% CI 18.39–19.70) in 2020. Similarly, the PsA incidence rate per 1,000 patient-years increased from 3.35 (95% CI 3.01–3.72) in 2008 to 5.01 (95% CI 4.68–5.36) in 2020. Patients with plaque PsO, moderate-to severe PsO, receiving oral systemic therapy or phototherapy, with a higher burden of comorbidities, and concomitant autoimmune diseases had a higher risk of PsA. The results provide insight into the burden of PsA among PsO patients in Korea and risk factors associated with developing PsA.
Downloads
References
McHugh N, Balachrishnan C, Jones S. Progression of peripheral joint disease in psoriatic arthritis: a 5- yr prospective study. Rheumatology 2003; 42: 778–783.
https://doi.org/10.1093/rheumatology/keg217 DOI: https://doi.org/10.1093/rheumatology/keg217
Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in Europe-an/North American dermatology clinics. J Am Acad Dermatol 2013; 69: 729–735.
https://doi.org/10.1016/j.jaad.2013.07.023 DOI: https://doi.org/10.1016/j.jaad.2013.07.023
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among pa-tients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 2010; 24: 548–554.
https://doi.org/10.1111/j.1468-3083.2009.03463.x DOI: https://doi.org/10.1111/j.1468-3083.2009.03463.x
Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predic-tors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis pa-tients: a systematic literature review and meta-analysis. Rheumatol Ther 2021; 8: 1519–1534.
https://doi.org/10.1007/s40744-021-00378-w DOI: https://doi.org/10.1007/s40744-021-00378-w
Lewinson RT, Vallerand IA, Lowerison MW, Parsons LM, Frolkis AD, Kaplan GG, et al. De-pression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol 2017; 137: 828–835.
https://doi.org/10.1016/j.jid.2016.11.032 DOI: https://doi.org/10.1016/j.jid.2016.11.032
Nguyen UDT, Zhang Y, Lu N, Louie-Gao Q, Niu J, Ogdie A, et al. Smoking paradox in the de-velopment of psoriatic arthritis among patients with psoriasis: a population-based study. Ann Rheum Dis 2018; 77: 119–123.
https://doi.org/10.1136/annrheumdis-2017-211625 DOI: https://doi.org/10.1136/annrheumdis-2017-211625
Eder L, Cohen AD, Feldhamer I, Greenberg-Dotan S, Batat E, Zisman D. The epidemiology of psoriatic arthritis in Israel: a population-based study. Arthritis Res Ther 2018; 20: 1–7.
https://doi.org/10.1186/s13075-017-1497-4 DOI: https://doi.org/10.1186/s13075-017-1497-4
Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard M-A, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol 2015; 73: 242–248.
https://doi.org/10.1016/j.jaad.2015.05.001 DOI: https://doi.org/10.1016/j.jaad.2015.05.001
Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge thera-pies. J Autoimmun 2017; 76: 21–37.
https://doi.org/10.1016/j.jaut.2016.10.009 DOI: https://doi.org/10.1016/j.jaut.2016.10.009
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.e219.
https://doi.org/10.1016/j.jaad.2018.06.027 DOI: https://doi.org/10.1016/j.jaad.2018.06.027
Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 2017; 32: 718–728.
https://doi.org/10.3346/jkms.2017.32.5.718 DOI: https://doi.org/10.3346/jkms.2017.32.5.718
Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol 1999; 149: 195–197.
https://doi.org/10.1093/oxfordjournals.aje.a009786 DOI: https://doi.org/10.1093/oxfordjournals.aje.a009786
Stuart EA. Matching methods for causal inference: a review and a look forward. Stat Sci 2010; 25: 1–21.
https://doi.org/10.1214/09-STS313 DOI: https://doi.org/10.1214/09-STS313
Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130–1139.
https://doi.org/10.1097/01.mlr.0000182534.19832.83 DOI: https://doi.org/10.1097/01.mlr.0000182534.19832.83
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173: 676–682.
https://doi.org/10.1093/aje/kwq433 DOI: https://doi.org/10.1093/aje/kwq433
Chen YT, Wu CY, Li YL, Chen LY, Chiou HY. Time trends in psoriasis and psoriatic arthritis incidence from 2002 to 2016 in Taiwan: an age-period-cohort analysis. J Clin Med 2022; 11: 3744.
https://doi.org/10.3390/jcm11133744 DOI: https://doi.org/10.3390/jcm11133744
Baek HJ, Yoo CD, Shin KC, Lee YJ, Kang SW, Lee EB, et al. Spondylitis is the most common pattern of psoriatic arthritis in Korea. Rheumatol Int 2000; 19: 89–94.
https://doi.org/10.1007/s002960050109 DOI: https://doi.org/10.1007/s002960050109
Karreman MC, Weel AE, van der Ven M, Vis M, Tchetverikov I, Nijsten TE, et al. Prevalence of psoriatic arthritis in primary care patients with psoriasis. Arthritis Rheumatol 2016; 68: 924–931.
https://doi.org/10.1002/art.39530 DOI: https://doi.org/10.1002/art.39530
Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, et al. Incidence of art-hritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) 2011; 63: 619–622.
https://doi.org/10.1002/acr.20401 DOI: https://doi.org/10.1002/acr.20401
Iskandar IYK, Chen TC, Chen LC, Lee MS, Yang YY, Wang TC, et al. Incidence, prevalence, and mortality of people with psoriasis and psoriatic arthritis in Taiwan: a nationwide co-hort study. Acta Derm Venereol 2022; 102: adv00807.
https://doi.org/10.2340/actadv.v102.1962 DOI: https://doi.org/10.2340/actadv.v102.1962
Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 2015; 5: e006450.
https://doi.org/10.1136/bmjopen-2014-006450 DOI: https://doi.org/10.1136/bmjopen-2014-006450
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.
https://doi.org/10.1136/bmj.m1590 DOI: https://doi.org/10.1136/bmj.m1590
Eder L, Widdifield J, Rosen CF, Cook R, Lee KA, Alhusayen R, et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken) 2019; 71: 1084–1091.
https://doi.org/10.1002/acr.23743 DOI: https://doi.org/10.1002/acr.23743
Spelman L, Su JC, Fernandez-Peñas P, Varigos GA, Cooper AJ, Baker CS, et al. Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. J Eur Acad Dermatol Venereol 2015; 29: 2184–2191.
https://doi.org/10.1111/jdv.13210 DOI: https://doi.org/10.1111/jdv.13210
Yang YS, Han BD, Han K, Jung JH, Son JW. Obesity fact sheet in Korea, 2021: trends in obe-sity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr 2022; 31: 169–177.
https://doi.org/10.7570/jomes22024 DOI: https://doi.org/10.7570/jomes22024
Barros G, Duran P, Vera I, Bermúdez V. Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci 2022; 23: 7499.
https://doi.org/10.3390/ijms23147499 DOI: https://doi.org/10.3390/ijms23147499
Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 2015; 17: 64.
https://doi.org/10.1007/s11926-015-0540-1 DOI: https://doi.org/10.1007/s11926-015-0540-1
Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with se-vere psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013; 72: 736–740.
https://doi.org/10.1136/annrheumdis-2012-201706 DOI: https://doi.org/10.1136/annrheumdis-2012-201706
Rosenthal YS, Schwartz N, Sagy I, Pavlovsky L. Incidence of psoriatic arthritis among pati-ents receiving biologic treatments for psoriasis: a nested case-control study. Arthritis Rheumatol 2022; 74: 237–243.
https://doi.org/10.1002/art.41946 DOI: https://doi.org/10.1002/art.41946
Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10: 318–325.
https://doi.org/10.18553/jmcp.2004.10.4.318 DOI: https://doi.org/10.18553/jmcp.2004.10.4.318
Carter LM, McGonagle D, Vital EM, Wittmann M. Applying early intervention strategies to autoimmune skin diseases. Is the window of opportunity preclinical? A dermato-rheumatology perspective. J Invest Dermatol 2022; 142: 944–950.
https://doi.org/10.1016/j.jid.2021.11.018 DOI: https://doi.org/10.1016/j.jid.2021.11.018
Iversen L, Eidsmo L, Austad J, de Rie M, Osmancevic A, Skov L, et al. Secukinumab treat-ment in new-onset psoriasis: aiming to understand the potential for disease modificat-ion – rationale and design of the randomized, multicenter STEPIn study. J Eur Acad Der-matol Venereol 2018; 32: 1930–1939.
https://doi.org/10.1111/jdv.14979 DOI: https://doi.org/10.1111/jdv.14979
Yan D, Ahn R, Leslie S, Liao W. Clinical and genetic risk factors associated with psoriatic arthritis among patients with psoriasis. Dermatol Ther (Heidelb) 2018; 8: 593–604.
https://doi.org/10.1007/s13555-018-0266-x DOI: https://doi.org/10.1007/s13555-018-0266-x
Andersen YMF, Augustin M, Petersen J, Hagenström K, Mallbris L, Burge R, et al. Charac-teristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol 2019; 181: 976–982.
https://doi.org/10.1111/bjd.17832 DOI: https://doi.org/10.1111/bjd.17832
Kim DH, Lee JY, Cho SI, Jo SJ. Risks of comorbidities in patients with palmoplantar pustu-losis vs patients with psoriasis vulgaris or pompholyx in Korea. JAMA Dermatol 2022; 158: 650–660.
https://doi.org/10.1001/jamadermatol.2022.1081 DOI: https://doi.org/10.1001/jamadermatol.2022.1081
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021; 41: 275–284.
https://doi.org/10.1007/s00296-020-04775-2 DOI: https://doi.org/10.1007/s00296-020-04775-2
Emmungil H, İlgen U, Direskeneli RH. Autoimmunity in psoriatic arthritis: pathophysiolo-gical and clinical aspects. Turk J Med Sci 2021; 51: 1601–1614.
https://doi.org/10.3906/sag-2011-235 DOI: https://doi.org/10.3906/sag-2011-235
Park B, Sung J, Park K, Seo S, Kim S. Strategies to improve the validity of diagnostic codes of national health insurance claims data. Health Insurance Review and Assessment Ser-vices; 2002: 118–119.
Koehm M, Behrens F. Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities. RMD Open 2023; 9: e003166.
https://doi.org/10.1136/rmdopen-2023-003166 DOI: https://doi.org/10.1136/rmdopen-2023-003166
Ogdie A, Scher JU. Prevention of psoriatic arthritis: the next frontier. Lancet Rheumatol 2023; 5: e170–e171.
https://doi.org/10.1016/S2665-9913(23)00055-3 DOI: https://doi.org/10.1016/S2665-9913(23)00055-3
Soriano ER, Ogdie A. Can early aggressive treatment of psoriasis prevent psoriatic arthri-tis? A debate at the GRAPPA annual meeting. J Rheumatol 2023; 50: 8–10.
https://doi.org/10.3899/jrheum.2023-0506 DOI: https://doi.org/10.3899/jrheum.2023-0506
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54: 685–704.
https://doi.org/10.1016/j.jaad.2005.10.008 DOI: https://doi.org/10.1016/j.jaad.2005.10.008
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Chul Hwan Bang, Yoon-Seob Kim, Jihye An, Eun Suk Jung, JiYoon Ahn, Jung-Ae Kim, Chul Jong Park
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
